Spasojević J, Pejin D, Stajnic S
Institut za interne bolesti, Medicinski fakultet, Novi Sad.
Med Pregl. 1997 May-Jun;50(5-6):224-8.
This study group comprised 58 patients with polycythemia vera. A retrospective study included 23/58 (39.60%) patients treated from 1968 to 1987, while a prospective study included 35/58 (60.34%) patients. Over the period 1986.-1996., 19/58 (32.76%) patients died: 10/23 (43.48%) from the retrospective group where mean disease duration was 12.7 years (6-24), and 9/35 (25.71%) from the prospective group where mean disease duration was 2.22 years (1-4). Erythrocytic phase of the disease was established in 50/58 (86.21%) patients; in 2/58 (3.45%) patients phase of spent hematopoiesis and postpolycythemic myeloid metaplasia in 6/58 (10.34%) patients. Postpolycythemic myeloid metaplasia has occurred after a mean time of 10.33 years (6-15) from establishing the first polycythemia. Two patients (10.53%) with postpolycythemic myeloid metaplasia died, one immediately after the diagnosis was established, the other patient two years after establishing the diagnosis. 16/19 (84.21%) patients died during the erythrocytic phase of the polycythemia vera, while 1/19 (5.26%) patient died in the phase of spent hematopoiesis. In regard to alive patients postpolycythemia myeloid metaplasia has been established in 4/39 (10.26%) patients, the phase of spent hematopoiesis in 1/39 (2.56%), while 34/39 (87.18%) patients are in the erythrocytic phase.
该研究组由58例真性红细胞增多症患者组成。一项回顾性研究纳入了1968年至1987年期间接受治疗的23/58(39.60%)例患者,而一项前瞻性研究纳入了35/58(60.34%)例患者。在1986年至1996年期间,19/58(32.76%)例患者死亡:回顾性研究组中有10/23(43.48%)例,其平均病程为12.7年(6 - 24年);前瞻性研究组中有9/35(25.71%)例,其平均病程为2.22年(1 - 4年)。50/58(86.21%)例患者处于疾病的红细胞期;2/58(3.45%)例患者处于造血耗竭期,6/58(10.34%)例患者处于真性红细胞增多症后骨髓化生期。真性红细胞增多症后骨髓化生在首次出现红细胞增多症平均10.33年(6 - 15年)后发生。2例(10.53%)真性红细胞增多症后骨髓化生患者死亡,1例在确诊后立即死亡,另1例在确诊后两年死亡。16/19(84.21%)例患者在真性红细胞增多症的红细胞期死亡,而1/19(5.26%)例患者在造血耗竭期死亡。在存活患者中,4/39(10.26%)例患者出现了真性红细胞增多症后骨髓化生,1/39(2.56%)例患者处于造血耗竭期,而34/39(87.18%)例患者处于红细胞期。